FY2025 EPS Estimates for ELDN Cut by Cantor Fitzgerald

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Equities researchers at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($1.23) per share for the year, down from their prior estimate of ($1.12). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Separately, Guggenheim assumed coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 target price for the company.

Eledon Pharmaceuticals Trading Down 2.9 %

ELDN opened at $3.37 on Wednesday. The stock’s 50-day moving average price is $4.14 and its 200 day moving average price is $3.88. Eledon Pharmaceuticals has a 12-month low of $1.52 and a 12-month high of $5.54. The firm has a market cap of $201.80 million, a price-to-earnings ratio of -1.68 and a beta of 0.80.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same period in the previous year, the business earned ($1.00) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. RA Capital Management L.P. acquired a new position in Eledon Pharmaceuticals during the 4th quarter worth $14,693,000. Sphera Funds Management LTD. lifted its position in shares of Eledon Pharmaceuticals by 96.7% during the 4th quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company’s stock worth $10,513,000 after purchasing an additional 1,254,298 shares during the last quarter. First Light Asset Management LLC acquired a new position in shares of Eledon Pharmaceuticals during the fourth quarter worth $9,595,000. Blue Owl Capital Holdings LP acquired a new position in shares of Eledon Pharmaceuticals during the fourth quarter worth $8,075,000. Finally, Woodline Partners LP raised its stake in Eledon Pharmaceuticals by 98.3% in the fourth quarter. Woodline Partners LP now owns 1,671,822 shares of the company’s stock valued at $6,888,000 after buying an additional 828,930 shares in the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).